On September 9, 2026 Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, reported that members of its management team will participate in the following industry and investor conferences in September 2026:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Oncology & Immunology Innovation Partnering & Licensing Summit
Presentation date: September 9, 2026
Location: Hotel Commonwealth, Boston, MA
Format: Presentation
Presenter: Dr. Mitchell Shirvan, Chief Scientific and Development Officer
8th Annual RAS-Targeted Drug Development Summit
Presentation date: September 10, 2026
Location: The Colonnade Hotel, Boston, MA
Format: Presentation
Presenter: Dr. Mitchell Shirvan, Chief Scientific and Development Officer
H.C. Wainwright 28th Annual Global Investment Conference
Dates: September 14–16, 2026
Location: Lotte New York Palace Hotel, New York, NY
Format: One-on-one meetings
Attendees: Ilan Hadar, Chief Executive Officer; Mirit Horenshtein Hadar, Chief Financial Officer
Parties interested in meeting with Silexion’s management during the conferences should contact their conference representative or the Company’s Investor Relations team to arrange a meeting.
Silexion is currently developing SIL204, an investigational pan-KRAS RNA interference therapy, in an ongoing Phase 2/3 clinical program in locally advanced pancreatic cancer.
(Press release, Silexion Therapeutics, SEP 9, 2026, View Source [SID1234670711])